Innate Pharma updates on its next meetings with analysts and investors
Innate Pharma reports 2010 financial results and updates on its drug candidates
Innate Pharma receives a milestone payment for IPH2201, a monoclonal antibody licensed to Novo Nordisk A/S
Innate Pharma SA reports annual operating revenue of 4.3 million euros for 2010
The US National Cancer Institute starts a Phase II clinical trial with Innate Pharma's IPH2101
Half-year report on Innate Pharma's liquidity contract with Natixis Securities
Innate Pharma announces today its tentative financial calendar for 2011
Initiation of a Phase II clinical trial with anti-KIR monoclonal antibody IPH2101 in smoldering myeloma patients
Innate Pharma announces today that it will participate to the “Life Science Day”
Innate Pharma announces its turnover for the first nine months of 2010 and updates on its cash situation
